FDA Inspections Unlikely Following Documented Manufacturing Changes
This article was originally published in The Gray Sheet
Executive Summary
FDA normally will not inspect the facilities of device companies with an approved PMA that report changes in manufacturing procedures via 30-day notices unless the Center for Devices and Radiological Health "determines that the notice is inadequate," the agency explains in a recent guidance.
You may also be interested in...
Supplementing MDUFMA: FDA Requests Industry/Staff Training Program Ideas
Industry has the opportunity to impart training to FDA staff as part of the implementation of Medical Device User Fee & Modernization Act training initiatives
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”